Pimavanserin Treatment for Parkinson’s Disease Psychosis in Clinical Practice
Background. Parkinson’s disease psychosis (PDP) is a common, nonmotor symptom of Parkinson’s disease (PD), which may affect up to 60% of patients and is associated with impaired quality of life, increased healthcare costs, and nursing home placement, among other adverse outcomes. Characteristic symp...
Main Authors: | Khashayar Dashtipour, Fiona Gupta, Robert A. Hauser, Cherian A. Karunapuzha, John C. Morgan |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2021-01-01
|
Series: | Parkinson's Disease |
Online Access: | http://dx.doi.org/10.1155/2021/2603641 |
Similar Items
-
Evidence for the use of pimavanserin in the treatment of Parkinson’s disease psychosis
by: Harini Sarva, et al.
Published: (2016-11-01) -
Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
by: Combs BL, et al.
Published: (2017-03-01) -
Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis
by: Armstrong, M.J, et al.
Published: (2021) -
Methods of synthesis of Pimavanserin: the first drug approved for the treatment of Parkinson's disease psychosis (PDP)
by: Nader Robin Al Bujuq
Published: (2020-02-01) -
Repurposing Pimavanserin, an Anti-Parkinson Drug for Pancreatic Cancer Therapy
by: Sharavan Ramachandran, et al.
Published: (2020-12-01)